Tomoka Gose

Tomoka Gose

Auto-generated profile, based on publicly available information

Tomoka Gose

Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
TGTomoka Gose
Tomoka Gose
HAHeather M. Aitken
Heather M. Aitken
YWYao Wang
Yao Wang
JLJohn Lynch
John Lynch
EREvadnie Rampersaud
Evadnie Rampersaud
JSJohn Schuetz
John Schuetz
ABCG2 is a medically important ATP-binding cassette transporter with crucial roles in the absorption and distribution of chemically-diverse toxins and drugs, reducing the cellular accumulation of chemotherapeutic drugs to facilitate multidrug resistance in cancer. ABCG2’s capacity to transport both hydrophilic and hydrophobic compounds is not well understood. Here we assess the molecular basis for substrate discrimination by the binding pocket. Substitution of a phylogenetically-conserved polar residue, N436, to alanine in the binding pocket of human ABCG2 permits only hydrophobic substrate transport, revealing the unique role of N436 as a discriminator. Molecular dynamics simulations show that this alanine substitution alters the electrostatic potential of the binding pocket favoring hydration of the transport pore. This change affects the contact with substrates and inhibitors, abrogating hydrophilic compound transport while retaining the transport of hydrophobic compounds. The N436 residue is also required for optimal transport inhibition of ABCG2, as many inhibitors are functionally impaired by this ABCG2 mutation. Overall, these findings have biomedical implications, broadly extending our understanding of substrate and inhibitor interactions.

18 November 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SBStefanie A. Baril
Stefanie A. Baril
KWKatie Wilson
Katie Wilson
MSMunan Shaik
Munan Shaik
YFYu Fukuda
Yu Fukuda
RURobyn A. Umans
Robyn A. Umans
JSJohn Schuetz
John Schuetz
ABCB6 has been implicated in dyschromatosis universalis hereditaria, a condition characterized by hyperpigmented and hypopigmented skin macules. Dyschromatosis universalis hereditaria can also present with hearing loss. Dyschromatosis universalis hereditaria-associated mutations in ABCB6 have been reported, but the role of this protein in the inner ear has not been studied. Here we determine a high-resolution (2.93 Å) cryo-EM structure of ABCB6 and functionally characterized several dyschromatosis universalis hereditaria mutants. We find that the L356P mutant abolishes ABCB6 function, and affirm the underlying loss of ATP binding mechanism using molecular dynamics simulations based on our cryo-EM structure. To test the role of ABCB6 in the inner ear, we characterize Abcb6 (the ABCB6 homolog) in zebrafish. We show that Abcb6 suppression by morpholinos reduces inner ear and lateral line hair cell numbers. Morphants also lack the utricular otolith, which is associated with vestibular function. Co-injecting morpholinos with human ABCB6 mRNA partially rescues the morphant phenotype, suggesting that Abcb6 plays a developmental role in inner ear structures. Further, we show that Abcb6 knockout mice exhibit an increased auditory brainstem response threshold, resulting in reduced hearing sensitivity. Taken together, these data suggest ABCB6 plays a role in inner ear development and function.

3 December 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
JZJingwen Zhu
Jingwen Zhu
SRSabina Ranjit
Sabina Ranjit
TGTomoka Gose
Tomoka Gose
ANAmanda Nourse
Amanda Nourse
VPVishwajeeth R. Pagala
Vishwajeeth R. Pagala
JSJohn Schuetz
John Schuetz
Cyclic AMP (cAMP) compartmentalization at the plasma membrane employs export by ABCC4, yet the protein machinery that creates spatially restricted signaling has remained unclear. We show that robust PKA activation increases ABCC4 at the cell surface and assembles a PDZ-dependent macromolecular complex that constrains ABCC4 mobility and stabilizes the transporter. Using Avi-tag crosslinking/AP-MS and APEX proximity labeling, we map a PKA-induced ABCC4 neighborhood enriched for PDZ-domain scaffolds that couple ABCC4 to actin and cell junctions. SCRIB emerges as a previously unrecognized interactor whose depletion lowers surface ABCC4 and blunts ABCC4-dependent drug resistance. Deleting the ABCC4 PDZ motif accelerates lateral diffusion ~4-fold, halves protein half-life, and attenuates PKA-stimulated increases in surface ABCC4 and cAMP efflux, establishing a requirement for the PDZ motif in optimal export under PKA drive. Finally, the selective ABCC4 inhibitor Ceefourin-2 lowers ABCC4’s melting temperature and dismantles the actin/junction–enriched neighborhood, revealing a non-classical small molecule inhibitory mechanism based on network disruption. These findings define a PKA-driven, PDZ-dependent ABCC4 protein neighborhood that stabilizes the transporter and optimizes cAMP efflux—an advance over prior work that localized ABCC4 but lacked a mechanistic blueprint for its membrane microdomain organization.

17 October 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
TGTomoka Gose
Tomoka Gose
HAHeather M. Aitken
Heather M. Aitken
YWYao Wang
Yao Wang
JLJohn Lynch
John Lynch
EREvadnie Rampersaud
Evadnie Rampersaud
JSJohn Schuetz
John Schuetz